CA Patent

CA3074563A1 — Sublingual epinephrine tablets

Assigned to Phase Pharmaceuticals LLC · Expires 2019-03-14 · 7y expired

What this patent protects

The present disclosure provides sublingual epinephrine tablets and methods of treating anaphylaxis, methods for concomitant therapy during a cardiac event, treating hypoglycemia, and prophylaxis for immunotherapy, using sublingual epinephrine tablets.

USPTO Abstract

The present disclosure provides sublingual epinephrine tablets and methods of treating anaphylaxis, methods for concomitant therapy during a cardiac event, treating hypoglycemia, and prophylaxis for immunotherapy, using sublingual epinephrine tablets.

Drugs covered by this patent

Patent Metadata

Patent number
CA3074563A1
Jurisdiction
CA
Classification
—
Expires
2019-03-14
Drug substance claim
No
Drug product claim
No
Assignee
Phase Pharmaceuticals LLC
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.